Reovirus inhibits the peritoneal dissemination of pancreatic cancer cells in an immunocompetent animal model

Oncology Reports

Volumn 21, Issue 6, 2009, Pages 1381-1384

  Hirano, Seitaro ^a   Etoh, Tsuyoshi ^a   Okunaga, Ryoki ^a   Shibata, Kohei ^a   Ohta, Masayuki ^a   Nishizono, Akira ^a   Kitano, Seigo ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Immunocompetent model; Pancreatic cancer; Peritoneal dissemination; Reovirus

Indexed keywords

ONCOLYTIC REOVIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS CANCER; PERITONEAL CAVITY; PERITONEUM METASTASIS; PRIORITY JOURNAL; SYRIAN HAMSTER; TUMOR VOLUME; VIRUS REPLICATION; ANIMAL; EXPERIMENTAL NEOPLASM; HAMSTER; INTRAPERITONEAL DRUG ADMINISTRATION; MAMMALIAN ORTHOREOVIRUS; METASTASIS; PANCREAS TUMOR; PATHOGENICITY; PATHOLOGY; PERITONEUM TUMOR; TIME; TUMOR CELL LINE; VIROLOGY;

ANIMALS; ASCITES; CELL LINE, TUMOR; CRICETINAE; IMMUNOCOMPETENCE; INJECTIONS, INTRAPERITONEAL; MALE; MAMMALIAN ORTHOREOVIRUS 3; MESOCRICETUS; NEOPLASMS, EXPERIMENTAL; ONCOLYTIC VIROTHERAPY; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; TIME FACTORS;

EID: 67649997035     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000364     Document Type: Article

References (22)

1. Micheal CS and Konstantinos GM: Pancreatic cancer today. Hepato-Gastroenterol 51: 862-868, 2004.
2. Niederhuber JE, Brennan MF and Menck HR: The National Cancer Data Base report on pancreatic cancer. Cancer 76: 1671-1677, 1995.
3. Birk D, Schoenberg MH, Gansauge F, Formentini A, Fortnagel G and Beger HG: Carcinoma of the head of the pancreas arising from the uncinate process. Br J Surg 85: 498-501, 1998.
4. del Castillo CF and Washaw L: Peritoneal metastasis in pamcreatic carcinoma. Hepato-Gastroenterol 40: 430-432, 1993.
5. Tyler KL and Fields BN: Reoviruses. In: Fields Viology. Fields BN, Knipe DM and Howley PM (eds). 3rd edition, Lippincott-Raven, Philadelphia, pp1597-1632, 1996.
6. Strong JE, Coffey MC, Tang D, Sabinin P and Lee PW: The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 17: 3351-3362, 1998.
7. Wilcox ME, Yang W, Senger D, Rewcastle NB, Morris DG, Brasher PM, Shi ZQ, Johnston RN, Nishikawa S, Lee PW and Forsyth PA: Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 93: 903-912, 2001.
8. Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A and Lee PW: Oncolytic reovirus against ovarian and colon cancer. Cancer Res 62: 1696-1701, 2002.
9. Alain T, Hirasawa K, Pon KJ, Nishikawa SG, Urbanski SJ, Auer Y, Luider J, Martin A, Johnston RN, Janowska-Wieczorek A, Lee PW and Kossakowska AE: Reovirus therapy of lymphoid malignancies. Blood 100: 4146-4153, 2002.
10. Norman KL, Coffey MC, Hirasawa K, Demetrick DJ, Nishikawa SG, DiFrancesco LM, Storong JE and Lee PW: Reovirus oncolysis of human breast cancer. Hum Gene Ther 13: 641-652, 2002.
11. Etoh T, Himeno Y, Matsumoto T, Aramaki M, Kawano K, Nishizono A and Kitano S: Oncolytic viral therapy for human pancreatic cancer cells by reovirus. Clin Cancer Res 9: 1218-1223, 2003.
12. Himeno Y, Etoh T, Matsumoto T, Ohta M, Nishizono A and Kitano S: Efficacy of oncolytic reovirus against liver metastasis from pancreatic cancer in immnocompetent models. Int J Oncol 27: 901-906, 2005.
13. Bierman HR, Crile DM, Dod KS, Kelly KH, Petrakis NL, White LP and Shimkim MB: Remissions in leukemia of childhood following acute infectious disease: staphylococcus and streptococcus, varicella, and feline panleukopenia. Cancer 6: 591-605, 1953.
14. Bluming AZ and Ziegler JL: Regression of Burkitt's lymphoma in association with measles infection. Lancet 10: 105-106, 1971.
15. Taqi AM, Abdurrahman MB, Yakubu AM and Fleming AF: Regression of Hodgkin's disease after measles. Lancet 16: 1112, 1981.
16. Andreansky S, He B, van Cott J, McGhee J, Markert JM, Gillespie GY, Roizman B and Whitley RJ: Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 5: 121-130, 1998.
17. Park KH, Kim G, Jang SH, Kim CH, Kwon SY, Yoo CG, Kim YW, Kwon HC, Kim CM, Han SK, Shim YS and Lee CT: Gene therapy with GM-CSF, interleukin-4 and herpes simplex virus thymidine kinase shows strong antitumor effect on lung cancer. Anticancer Res 23: 1559-1564, 2003.
18. Dewey RA, Morrissey G, Cowsill CM, Stone D, Bolognani F, Dodd NJ, Southgate TD, Klatzmann D, Lassmann H, Castro MG and Löwenstein PR: Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat Med 5: 1256-1263, 199.
19. Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, Kovatich AJ and Lattime EC: Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 6: 409-422, 1999.
20. Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL, Goldberg S, Gross P, O'Neil JD, Groene WS, Roberts MS, Rabin H, Bamat MK and Lorence RM: Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 20: 2251-2266, 2002.
21. Nemunaitis J, Cunningham C, Buchanan A, Blackburn A, Edelman G, Maples P, Netto G, Tong A, Randlev B, Olson S and Kirn D: Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 8: 746-759, 2001.
22. Morris D, Forsyth PA, Patherson AH, et al: A phase I clinical trial evaluating intralesional Reolysin (reovirus) in histologically confirmed malignancies. Proc Am Soc Clin Oncol Annu Meet 21: 92: 24, 2002.